The NAD Booster Reached Phase 3. It Did Not Slow Parkinson’s.

NAD has become one of the most recognizable molecules in longevity science.

It is involved in cellular energy production, DNA repair and multiple signaling pathways. Its levels can change with age, and experiments in animals have linked NAD biology to metabolism, mitochondrial function and aspects of age-related decline.

That has helped make “NAD boosting” a commercial category.

Supplements containing nicotinamide riboside, or NR, are sold with promises surrounding cellular energy, healthy aging and resilience. In medicine, researchers have also investigated whether increasing NAD availability could affect diseases involving mitochondrial dysfunction and neurodegeneration.

Parkinson disease was one of the most serious tests of that idea.

On October 8, 2026, researchers reported results from NOPARK: a Phase 3 randomized trial testing nicotinamide riboside in people with early Parkinson disease.

The supplement produced clear biological activity in the blood.

It did not improve the primary clinical outcome.

Participants assigned to NR instead had slightly worse clinical scores than those assigned to placebo.

That does not establish that NAD supplements are broadly dangerous. It does not answer every question about NR, other NAD precursors or healthy aging.

But it does challenge one of the most persistent assumptions in modern health optimization:

If a compound changes a promising biological pathway, meaningful health benefits will follow.

Why researchers thought NAD might matter

Nicotinamide adenine dinucleotide, usually shortened to NAD, is essential to cellular metabolism.

It helps cells convert nutrients into usable energy and participates in processes involving mitochondrial function, oxidative stress, inflammation, DNA repair and protein maintenance.

Those mechanisms are relevant to Parkinson disease.

Parkinson’s involves the progressive loss and dysfunction of dopamine-producing neurons. Although its biology is complex, mitochondrial impairment, oxidative stress, inflammation and disrupted cellular maintenance have all been implicated.

In laboratory models, interventions targeting NAD metabolism produced enough encouraging evidence to justify human research.

Early clinical studies added to the interest.

The 2022 NADPARK Phase 1 trial found that nicotinamide riboside could increase cerebral NAD in some participants with Parkinson disease. Researchers also observed changes in brain metabolism, inflammatory markers and gene-expression pathways, along with exploratory clinical signals.

A subsequent short safety trial, NR-SAFE, found that a larger amount of NR was tolerated over four weeks and substantially changed systemic NAD metabolism.

Those studies answered important early questions:

• Can the compound reach its biological target?
• Does it change NAD metabolism?
• Is short-term administration feasible?
• Are there signals worth studying in a larger trial?

They were not designed to prove that NR slowed Parkinson disease.

NOPARK was.

What the Phase 3 trial tested

NOPARK was a randomized, double-blind, placebo-controlled trial conducted at 11 centers in Norway.

Researchers enrolled 410 adults with relatively early Parkinson disease. Participants had been diagnosed within the previous two years, had imaging evidence of dopaminergic neurodegeneration and were receiving stable, optimized Parkinson medication.

They were randomly assigned to nicotinamide riboside or placebo for 52 weeks. The protocol used 500 milligrams twice daily; that is a description of the trial, not a recommendation for use.

The primary outcome was the combined score from parts I through III of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale, or MDS-UPDRS.

The scale evaluates several dimensions of Parkinson disease, including:

• experiences of daily living,
• nonmotor symptoms,
• motor symptoms, and
• findings on a clinician-administered motor examination.

Scores can range from zero to 236. Higher scores indicate worse disease.

This was not simply a study asking whether NR raised NAD in the bloodstream.

It asked whether people were clinically better after one year.

The result was not merely “no significant benefit”

At 52 weeks, the adjusted mean MDS-UPDRS score had increased by 2.45 points in the nicotinamide riboside group, indicating worsening.

In the placebo group, the score decreased by 0.27 points.

The adjusted difference was 2.72 points in favor of placebo. The 95% confidence interval ranged from 0.47 to 4.98 points, and the result was statistically significant.

That deserves careful interpretation.

The difference favored placebo, but it was smaller than the 5.2-point threshold the researchers cited for clinically important worsening on the scale.

In other words, the study detected a statistically credible difference, but the average magnitude may not have been large enough for patients to consistently perceive as a meaningful deterioration.

Four of the five key secondary outcomes did not differ significantly between groups. Nonmotor symptoms were the exception: they worsened more in the NR group.

Dopamine-transporter imaging did not show a significant difference suggesting faster loss of dopaminergic neurons with NR. However, the researchers noted that this type of imaging may not be sensitive enough to detect modest changes over one year.

The most defensible conclusion is therefore narrower than either extreme:

NR did not improve clinical outcomes in this trial. The primary outcome modestly favored placebo, but the study does not establish that NR accelerated the underlying neurodegenerative process.

The biology moved. The patient outcome did not.

NOPARK also measured metabolic changes.

NR produced a robust response in blood markers of NAD metabolism, confirming that participants received a biologically active intervention.

But at 52 weeks, researchers did not find a significant difference between groups in the measured cerebral NAD-related signal.

That finding differs from the earlier, much shorter NADPARK study, in which some participants showed increased brain NAD after approximately one month.

There are several possible explanations. The measurement methods, study populations and treatment durations differed. A short-term metabolic response may not persist in the same form. Blood target engagement may not reliably indicate what is happening in the brain. The biological pathway may also be affected without producing a useful clinical effect.

The trial cannot identify one definitive explanation.

What it does show is that biological plausibility and target engagement were not enough.

The intervention altered the pathway it was supposed to alter. That did not translate into better symptoms or function over 52 weeks.

Did nicotinamide riboside make Parkinson’s worse?

The primary clinical score was statistically worse with NR than with placebo, so the finding should not be dismissed.

But “NR worsens Parkinson’s” would be too broad a conclusion.

First, the average difference was below the trial’s threshold for clinically important worsening.

Second, the imaging result did not show evidence of more rapid dopaminergic neurodegeneration.

Third, the placebo group changed very little—and improved slightly on the primary scale. The trial’s standardized optimization of Parkinson medication may have influenced both groups and made progression harder to interpret.

Fourth, participants were evaluated while taking their usual Parkinson medications. That reflects real clinical practice, but it can partially obscure underlying changes in disease progression.

Finally, the trial lasted one year. That is substantial for a supplement study, but Parkinson disease develops over many years.

The result is strong evidence against clinical benefit from this regimen in this population over 52 weeks. It is less definitive evidence about whether NR caused meaningful harm or altered the underlying disease itself.

Evidence strength

What the evidence now shows with relatively high confidence

For people with early, treated Parkinson disease similar to the NOPARK participants, this NR regimen did not improve symptoms or function over one year.

The trial was large for this field, randomized, blinded, placebo-controlled and designed around a clinically relevant primary outcome.

Its findings do not support NR as a symptomatic or disease-modifying Parkinson treatment.

What remains uncertain

It remains uncertain why the primary score favored placebo.

The difference could reflect a small adverse effect, chance variation within a statistically significant result, interactions with treatment or disease biology, or limitations in how progression was measured.

The trial also cannot determine whether a different duration, population or NAD-directed strategy would produce a different result.

What the study did not test

NOPARK was not a longevity trial.

It did not study healthy adults trying to improve energy or slow aging. It did not measure lifespan, disability-free survival, cardiovascular events, cognitive decline or overall healthy aging.

It also did not test every NAD precursor, delivery method or formulation.

Using this study to claim that every form of NAD supplementation is harmful would exceed the evidence.

Using it to continue implying that raising NAD is already proven to improve human longevity would exceed the evidence too.

Who these results apply to

The trial most directly applies to adults with early Parkinson disease who:

• had been diagnosed within approximately two years,
• had imaging evidence consistent with dopaminergic neurodegeneration,
• were taking stable Parkinson medication, and
• were treated and followed in specialist centers.

Its applicability is less certain for people with later-stage disease, untreated disease, different clinical subtypes or substantially different health profiles.

For healthy consumers, the result is indirect but still important.

It does not tell a healthy person exactly what NR will do. It does show that an intervention can raise metabolites associated with NAD biology without producing the clinical benefit its mechanism seemed to predict.

That is a lesson with relevance far beyond Parkinson disease.

Safety context

Overall adverse-event rates were similar between groups: approximately 55% of participants receiving NR and 54% receiving placebo reported at least one adverse event.

In the safety population, serious adverse events occurred in 17 of 205 participants receiving NR (8.3%) and 29 of 205 receiving placebo (14.1%). Serious adverse events therefore were not more common overall in the NR group.

Some individual events, including hypertension and folate deficiency, occurred numerically more often with NR, but the study was not necessarily powered to determine whether those differences were causal.

There were two deaths during the trial—one in each group—and neither pattern established a clear general safety signal.

This matters because the difference in clinical scores should not be casually reframed as generalized toxicity. The safety data and the efficacy result answer different questions.

The study also should not be used as a reason to abruptly start or stop a supplement. Parkinson symptoms, prescribed therapies, other medications and supplements should be reviewed together with a qualified practitioner.

Transparency: The trial was publicly funded by the Research Council of Norway, the K. G. Jebsen Foundation, the Western Norway Regional Health Authority and KlinBeForsk. ChromaDex, a Niagen Bioscience company and maker of commercial nicotinamide riboside, supplied the NR and placebo. According to the authors, the funders had no role in the study’s design, analysis or publication.

The larger lesson for longevity science

Many interventions in longevity begin with a compelling chain of reasoning:

1. A biological feature changes with age or disease.
2. That feature appears to matter in cells or animals.
3. An intervention changes the feature in humans.
4. Therefore, the intervention should improve human health.

The fourth step is frequently assumed before it is demonstrated.

A biomarker may be causally important, merely correlated with the condition, or important only within a particular biological context. Raising or lowering it may also fail to recreate the complex conditions associated with health.

Even genuine target engagement does not guarantee that the intervention reaches the correct tissue, acts for the right duration or improves an outcome a person can feel.

This is why later-stage randomized trials matter.

Early mechanistic studies help decide what deserves testing. They should not be mistaken for the final test.

NOPARK moved the NAD hypothesis from biochemical promise to a meaningful clinical comparison.

The clinical result did not confirm the promise.

That is not a failure of science. It is science doing the job that marketing often skips.

What readers should actually do

If you have Parkinson disease, this trial is a reason not to treat nicotinamide riboside as a proven way to slow the disease. It should not replace established care or decisions made with a neurologist.

If you already take NR or another NAD-related supplement, do not make an abrupt change based only on a headline. Bring the supplement, its exact ingredients and your reason for taking it to your clinician or pharmacist.

If you are considering an NAD product for healthy aging, ask what human outcome has actually been demonstrated for people like you.

A rise in blood NAD metabolites is evidence that a product affected a pathway. It is not, by itself, evidence of improved energy, brain health, function or longevity.

The relevant question is not simply:

Did the biomarker move?

It is:

Did the person benefit?

Questions for your clinician

• What specific outcome am I trying to improve with this supplement?
• Is that outcome supported by randomized human evidence in people similar to me?
• If I have Parkinson disease, does NOPARK change how you view nicotinamide riboside?
• Could the supplement interact with my medications or make changes in my symptoms harder to interpret?
• Are there health conditions or laboratory findings that would make this product less appropriate for me?
• What would count as a meaningful benefit—and when would we conclude that it is not helping?
• Is there a more established way to address the goal for which I am considering it?

The Modern Bio Take

NOPARK does not close the book on NAD biology.

It does close an important gap between an attractive mechanism and a tested clinical claim.

Nicotinamide riboside changed NAD metabolism. In this well-controlled Phase 3 trial, it did not improve early Parkinson disease. The primary outcome modestly favored placebo, although the size and mechanism of that difference remain uncertain.

For longevity-minded readers, the broader message is simple:

A pathway can be biologically real. A supplement can reach that pathway. The biomarker can move.

And the person may still receive no meaningful benefit.

Better measurement is useful. Better outcomes are the standard that ultimately matters.

Educational note: This article is for general educational purposes and is not medical advice. It does not provide diagnosis, dosing, prescribing or individualized treatment guidance. Supplements, laboratory findings and treatment decisions should be considered in the context of an individual’s medical history, symptoms, medications and qualified healthcare practitioner.

Primary sources

• Brakedal B, Skeie GO, Derad C, et al. Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial. JAMA. Published online October 8, 2026. doi:10.1001/jama.2026.18828.

• NOPARK trial registration — NCT03568968. ClinicalTrials.gov.

• Brakedal B, Dölle C, Riemer F, et al. The NADPARK Study: A Randomized Phase I Trial of Nicotinamide Riboside Supplementation in Parkinson’s Disease. Cell Metabolism. March 1, 2022. doi:10.1016/j.cmet.2022.02.001.

• Berven H, Kverneng S, Sheard E, et al. NR-SAFE: A Randomized, Double-Blind Safety Trial of High-Dose Nicotinamide Riboside in Parkinson’s Disease. Nature Communications. November 28, 2023. doi:10.1038/s41467-023-43514-6.